SCHEMBL8437346

SCHEMBL8437346

Bc1n[nH]c2ccc(-c3n[nH]c(CC(C)C)n3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.43
DYRK1A Q13627 9/20 0.43
JAK2 O60674 4/20 0.43
GSK3B P49841 3/20 0.43
CDC7 O00311 1/20 0.43
PLK4 O00444 1/20 0.43
DCLK1 O15075 1/20 0.43
MAPK13 O15264 1/20 0.43
DAPK3 O43293 1/20 0.43
DYRK3 O43781 1/20 0.43
ROCK2 O75116 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
NTRK1 P04629 1/20 0.43
CDK1 P06493 1/20 0.43
RET P07949 1/20 0.43
ROS1 P08922 1/20 0.43
PRKACA P17612 1/20 0.43
RPS6KB1 P23443 1/20 0.43
CDK2 P24941 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5383014 0.86 CSNK1D (0.42) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL5372967 0.83 CSNK1D (0.64) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL5377949 0.82 CSNK1D (0.54) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL5378295 0.81 CSNK1D (0.51) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL5387119 0.80 CSNK1D (0.45) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL5386736 0.80 CSNK1D (0.45) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL5383966 0.79 CSNK1D (0.49) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL5381806 0.79 JAK2 (0.48) CSNK1DDYRK1AJAK2ROCK2MAPK1
SCHEMBL5378169 0.79 CSNK1D (0.44) CSNK1DDYRK1AJAK2GSK3BCDC7
SCHEMBL8442884 0.79 CSNK1D (0.44) CSNK1DDYRK1AJAK2GSK3BCDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R CSNK1D 410/4885DYRK1A 426/4885JAK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.